Desipramine in the treatment of children with attention deficit disorder.
Eighteen children with attention deficit disorder were treated with desipramine in a prospective open trial to assess its efficacy and safety. Improvement occurred within 4 weeks and was sustained without significant adverse effects for up to 52 weeks.
D001289:Attention Deficit Disorder with Hyperactivity / Q000097:blood / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D003891:Desipramine / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male
D003891:Desipramine